Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

bioportfolio.co.uk SUZHOU, China, May 31, 2020 /PRNewswire/BioPortfolio.co.uk/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the results of...
http://dlvr.it/RXkQRC

Comments

Popular posts from this blog

Global Commercial Gas Deep Fryer Market Data Survey Report 20152025 Prices from USD $1500